{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:33:45Z","timestamp":1791862425010,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The regular use of patient-reported measures (PRMs) has been associated with greater patient satisfaction and outcomes. In this article, we will review the Calgary Comprehensive Epilepsy Program's successful experience with PRMs in both clinical and research settings, as well as our current challenges and future directions. Our experience will illustrate that is feasible and convenient to implement PRMs, and especially electronic PRMs (ePRMs), into epilepsy clinics. These PRMs have direct clinical and research applications. They inform clinical decision making through readily interpretable scales to which clinicians can expeditiously respond. Equally, they are increasingly forming an integral and central component of intervention and outcomes-based research. However, implementation studies are necessary to address knowledge gaps and facilitate adoption and dissemination of this approach. A natural symbiosis of the clinical and research realms is precision medicine. The foundations of precision-based interventions are now being set whereby we can maximize the quality of life and psychosocial functioning on an individual level. As illustrated in this article, this exciting prospect crucially depends on the routine use of ePRMs in the everyday care of people with epilepsy. Increasing ePRMs uptake will clearly be a catalyst propelling precision epilepsy from aspiration to clinical reality.<\/jats:p>","DOI":"10.1186\/s41687-021-00356-4","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T12:08:32Z","timestamp":1634040512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The use of patient-reported measures in epilepsy care: the Calgary Comprehensive Epilepsy Program experience"],"prefix":"10.1186","volume":"5","author":[{"given":"Guillermo","family":"Delgado-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Wiebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7052-1651","authenticated-orcid":false,"given":"Colin B.","family":"Josephson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"356_CR1","doi-asserted-by":"crossref","unstructured":"Wasson J, Keller A, Rubenstein L, Hays R, Nelson E, Johnson D. Benefits and obstacles of health status assessment in ambulatory settings. The clinician's point of view. The Dartmouth Primary Care COOP Project. Med Care. 1992;30(5 Suppl):MS42\u20139.","DOI":"10.1097\/00005650-199205001-00004"},{"key":"356_CR2","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/epi.16526","volume":"61","author":"CB Josephson","year":"2020","unstructured":"Josephson CB, Engbers JDT, Wang M et al (2020) Psychosocial profiles and their predictors in epilepsy using patient-reported outcomes and machine learning. Epilepsia 61:1201\u20131210","journal-title":"Epilepsia"},{"key":"356_CR3","doi-asserted-by":"crossref","unstructured":"Nelson EC, Eftimovska E, Lind C, Hager A, Wasson JH, Lindblad S. Patient reported outcome measures in practice. BMJ. 2015;350:g7818.","DOI":"10.1136\/bmj.g7818"},{"key":"356_CR4","first-page":"59","volume":"17","author":"RG Beran","year":"1980","unstructured":"Beran RG, Read T (1980) Patient perspectives of epilepsy. Clin Exp Neurol 17:59\u201369","journal-title":"Clin Exp Neurol"},{"issue":"3","key":"356_CR5","first-page":"425","volume":"41","author":"T Soga","year":"1987","unstructured":"Soga T (1987) Restrictions on daily life\u2019s quality among people with epilepsy. Jpn J Psychiatry Neurol 41(3):425\u2013428","journal-title":"Jpn J Psychiatry Neurol"},{"issue":"1","key":"356_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S0895-4356(02)00537-1","volume":"56","author":"S Wiebe","year":"2003","unstructured":"Wiebe S, Guyatt G, Weaver B, Matijevic S, Sidwell C (2003) Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol 56(1):52\u201360","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"356_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.jval.2016.03.1860","volume":"20","author":"B Mulhern","year":"2017","unstructured":"Mulhern B, Pink J, Rowen D, Borghs S, Butt T, Hughes D, Marson A, Brazier J (2017) Comparing generic and condition-specific preference-based measures in epilepsy: EQ-5D-3L and NEWQOL-6D. Value Health 20(4):687\u2013693","journal-title":"Value Health"},{"issue":"2","key":"356_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/BF01833604","volume":"4","author":"BP Hermann","year":"1995","unstructured":"Hermann BP (1995) The evolution of health-related quality of life assessment in epilepsy. Qual Life Res 4(2):87\u2013100","journal-title":"Qual Life Res"},{"issue":"1","key":"356_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1528-1157.1998.tb01278.x","volume":"39","author":"JA Cramer","year":"1998","unstructured":"Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B (1998) Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia 39(1):81\u201388","journal-title":"Epilepsia"},{"issue":"11","key":"356_CR10","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/j.1528-1157.1995.tb00467.x","volume":"36","author":"O Devinsky","year":"1995","unstructured":"Devinsky O, Vickrey BG, Cramer J, Perrine K, Hermann B, Meador K, Hays RD (1995) Development of the quality of life in epilepsy inventory. Epilepsia 36(11):1089\u20131104","journal-title":"Epilepsia"},{"issue":"5","key":"356_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S1474-4422(06)70415-X","volume":"5","author":"FG Gilliam","year":"2006","unstructured":"Gilliam FG, Barry JJ, Hermann BP, Meador KJ, Vahle V, Kanner AM (2006) Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol 5(5):399\u2013405","journal-title":"Lancet Neurol"},{"issue":"4","key":"356_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/00005650-199204000-00002","volume":"30","author":"BG Vickrey","year":"1992","unstructured":"Vickrey BG, Hays RD, Graber J, Rausch R, Engel J Jr, Brook RH (1992) A health-related quality of life instrument for patients evaluated for epilepsy surgery. Med Care 30(4):299\u2013319","journal-title":"Med Care"},{"key":"356_CR13","doi-asserted-by":"crossref","unstructured":"Wiebe S, Blume WT, Girvin JP, Eliasziw M. Effectiveness and efficiency of surgery for temporal lobe epilepsy study group. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001;345(5):311\u20138.","DOI":"10.1056\/NEJM200108023450501"},{"issue":"5","key":"356_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1046\/j.1528-1157.2002.32201.x","volume":"43","author":"GL Birbeck","year":"2002","unstructured":"Birbeck GL, Hays RD, Cui X, Vickrey BG (2002) Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 43(5):535\u2013538","journal-title":"Epilepsia"},{"issue":"1","key":"356_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0920-1211(00)00127-3","volume":"41","author":"JA Cramer","year":"2000","unstructured":"Cramer JA, Arrigo C, Van Hamm\u00e9e G, Bromfield EB (2000) Comparison between the QOLIE-31 and derived QOLIE-10 in a clinical trial of levetiracetam. Epilepsy Res 41(1):29\u201338","journal-title":"Epilepsy Res"},{"issue":"10","key":"356_CR16","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10):1727\u20131736","journal-title":"Qual Life Res"},{"key":"356_CR17","doi-asserted-by":"publisher","first-page":"106392","DOI":"10.1016\/j.yebeh.2019.06.035","volume":"99","author":"Z Wang","year":"2019","unstructured":"Wang Z, Luo Z, Li S, Luo Z, Wang Z (2019) Anxiety screening tools in people with epilepsy: A systematic review of validated tools. Epilepsy Behav 99:106392","journal-title":"Epilepsy Behav"},{"key":"356_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.yebeh.2015.07.036","volume":"51","author":"TT Sajobi","year":"2015","unstructured":"Sajobi TT, Jette N, Zhang Y, Patten SB, Fiest KM, Engbers JD, Lowerison MW, Wiebe S (2015) Determinants of disease severity in adults with epilepsy: results from the neurological diseases and depression study. Epilepsy Behav 51:170\u2013175","journal-title":"Epilepsy Behav"},{"issue":"9","key":"356_CR19","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1111\/epi.13102","volume":"56","author":"TT Sajobi","year":"2015","unstructured":"Sajobi TT, Jette N, Fiest KM, Patten SB, Engbers JD, Lowerison MW, Wiebe S (2015) Correlates of disability related to seizures in persons with epilepsy. Epilepsia 56(9):1463\u20131469","journal-title":"Epilepsia"},{"issue":"5","key":"356_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/epi.13651","volume":"58","author":"SJ Gill","year":"2017","unstructured":"Gill SJ, Lukmanji S, Fiest KM, Patten SB, Wiebe S, Jett\u00e9 N (2017) Depression screening tools in persons with epilepsy: a systematic review of validated tools. Epilepsia 58(5):695\u2013705","journal-title":"Epilepsia"},{"key":"356_CR21","doi-asserted-by":"crossref","unstructured":"Panelli RJ, Kilpatrick C, Moore SM, Matkovic Z, D'Souza WJ, O'Brien TJ. The liverpool adverse events profile: relation to AED use and mood. Epilepsia. 2007;48(3):456\u201363.","DOI":"10.1111\/j.1528-1167.2006.00956.x"},{"issue":"Pt A","key":"356_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.yebeh.2016.02.015","volume":"57","author":"JA Micoulaud-Franchi","year":"2016","unstructured":"Micoulaud-Franchi JA, Lagarde S, Barkate G, Dufournet B, Besancon C, Tr\u00e9buchon-Da Fonseca A, Gavaret M, Bartolomei F, Bonini F, McGonigal A (2016) Rapid detection of generalized anxiety disorder and major depression in epilepsy: validation of the GAD-7 as a complementary tool to the NDDI-E in a French sample. Epilepsy Behav 57(Pt A):211\u2013216","journal-title":"Epilepsy Behav"},{"key":"356_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.yebeh.2018.12.006","volume":"92","author":"DH Kim","year":"2019","unstructured":"Kim DH, Kim YS, Yang TW, Kwon OY (2019) Optimal cutoff score of the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) for detecting major depressive disorder: a meta-analysis. Epilepsy Behav 92:61\u201370","journal-title":"Epilepsy Behav"},{"issue":"11","key":"356_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1477-7525-11-38","volume":"11","author":"A Nixon","year":"2013","unstructured":"Nixon A, Kerr C, Breheny K, Wild D (2013) Patient Reported Outcome (PRO) assessment in epilepsy: a review of epilepsy-specific PROs according to the Food and Drug Administration (FDA) regulatory requirements. Health Qual Life Outcomes 11(11):38","journal-title":"Health Qual Life Outcomes"},{"key":"356_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16709","author":"S Wiebe","year":"2020","unstructured":"Wiebe S, Wahby S, Lawal OA, Sajobi TT, Keezer MR, Nguyen DK, Malmgren K, Tellez-Zenteno J, Atkinson MJ, Hader WJ, Josephson CB, Macrodimitris S, Patten SB, Pillay N, Sharma R, Singh S, Starreveld Y (2020) Development and validation of the Epilepsy Surgery Satisfaction Questionnaire (ESSQ-19). Epilepsia. https:\/\/doi.org\/10.1111\/epi.16709","journal-title":"Epilepsia"},{"issue":"3","key":"356_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.yebeh.2011.04.011","volume":"21","author":"WM Sweileh","year":"2011","unstructured":"Sweileh WM, Ihbesheh MS, Jarar IS, Taha AS, Sawalha AF, Zyoud SH, Jamous RM, Morisky DE (2011) Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy Behav 21(3):301\u2013305","journal-title":"Epilepsy Behav"},{"key":"356_CR27","doi-asserted-by":"crossref","unstructured":"Subotic A, Pricop DF, Josephson CB, Patten SB, Smith EE, Roach P; Calgary Comprehensive Epilepsy Program Collaborators. Examining the impacts of the COVID-19 pandemic on the well-being and virtual care of patients with epilepsy. Epilepsy Behav. 2020;113:107599.","DOI":"10.1016\/j.yebeh.2020.107599"},{"issue":"6","key":"356_CR28","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Mosh\u00e9 SL, Perucca E, Wiebe S, French J (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51(6):1069\u20131077","journal-title":"Epilepsia"},{"issue":"6","key":"356_CR29","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/epi.13373","volume":"57","author":"M Mula","year":"2016","unstructured":"Mula M, McGonigal A, Micoulaud-Franchi JA, May TW, Labudda K, Brandt C (2016) Validation of rapid suicidality screening in epilepsy using the NDDIE. Epilepsia 57(6):949\u2013955","journal-title":"Epilepsia"},{"issue":"2","key":"356_CR30","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/epi.13974","volume":"59","author":"S Lukmanji","year":"2018","unstructured":"Lukmanji S, Sauro KM, Josephson CB, Altura KC, Wiebe S, Jett\u00e9 N (2018) A longitudinal cohort study on the impact of the clobazam shortage on patients with epilepsy. Epilepsia 59(2):468\u2013478","journal-title":"Epilepsia"},{"issue":"8","key":"356_CR31","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/jnnp-2018-319780","volume":"90","author":"S Wahby","year":"2019","unstructured":"Wahby S, Karnik V, Brobbey A, Wiebe S, Sajobi T, Josephson CB (2019) Cannabis use is both independently associated with and mediates worse psychosocial health in patients with epilepsy. J Neurol Neurosurg Psychiatry 90(8):945\u2013951","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"356_CR32","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s10198-017-0928-0","volume":"19","author":"BFM Wijnen","year":"2018","unstructured":"Wijnen BFM, Mosweu I, Majoie MHJM, Ridsdale L, de Kinderen RJA, Evers SMAA, McCrone P (2018) A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of QOLIE-31P to EQ-5D-5L in epilepsy. Eur J Health Econ 19(6):861\u2013870","journal-title":"Eur J Health Econ"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-021-00356-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-021-00356-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-021-00356-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T12:10:15Z","timestamp":1634040615000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-021-00356-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":32,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["356"],"URL":"https:\/\/doi.org\/10.1186\/s41687-021-00356-4","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"12 October 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GD-G is a National Researcher (Level I) of the Mexican System of Researchers, Mexican Council for Science and Technology (CVU: 613905). SW has nothing to declare. CBJ has received unrestricted educational grants from UCB Inc. and Eisai Inc. for work unrelated to this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}